SI3140296T1 - Pirolidin gpr40 modulatorji za zdravljenje bolezni kot je sladkorna bolezen - Google Patents

Pirolidin gpr40 modulatorji za zdravljenje bolezni kot je sladkorna bolezen Download PDF

Info

Publication number
SI3140296T1
SI3140296T1 SI201530232T SI201530232T SI3140296T1 SI 3140296 T1 SI3140296 T1 SI 3140296T1 SI 201530232 T SI201530232 T SI 201530232T SI 201530232 T SI201530232 T SI 201530232T SI 3140296 T1 SI3140296 T1 SI 3140296T1
Authority
SI
Slovenia
Prior art keywords
substituted
alkyl
independently selected
alkoxy
halogen
Prior art date
Application number
SI201530232T
Other languages
English (en)
Inventor
Elizabeth A. Jurica
Zhenqiu Hong
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI3140296T1 publication Critical patent/SI3140296T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (15)

  1. PIROLIDIN GPR40 MODULATORJI ZA ZDRAVLJENJE BOLEZNI KOT JE SLADKORNA BOLEZEN PATENTNI ZAHTEVKI
    1. Spojina s formulo (I):
    ali njena stereoizomera, tavtomera, farmacevtsko sprejemljiva sol, polimorf ali solvat, kjer: X je neodvisno izbran izmed:, O, S, NH, N(Ci-4 alkila), CH2, CH2CH2, CH(Ci-4 alkila), OCH2, CH2O OCH2CH2, in CH2CH2O obroč A je neodvisno
    obroč B je neodvisno 4- do 7- členski nasičen heterocikel, ki vsebuje atome ogljika, atom dušika, prikazan v obroču B, in 0-1 dodaten heteroatom, izbran izmed N, O in S; in obroč B je substituiran z 0-4 R2; R1 je neodvisno
    fenil, benzil, naftil ali 5- do 10-členski heteroaril, ki vsebujejo atome ogljika, in 1-4 heteroatome, izbrane izmed N, NR11, O in S; pri čemer so omenjeni fenil, benzil, naftil in heteroaril vsakokrat substituirani z 0-3 R6; R2 je v vsakem primeru neodvisno izbran izmed: = O, OH, halogena, C1-6 alkila, substituiranega z 0-1 R12, C1-6 alkoksija substituiranega z 0-1 R12, Ci-4 haloalkila, substituiranega z 0-1 R12, C1-4 haloalkoksija, substituiranega z 0-1 R12, - (CH2) m- C3-6 karbocikla, substituiranega z 0-1 R12, in - (CH2)m- (5- do 10-členski heteroaril, ki vsebuje ogljikove atome in 1- 4 heteroatome, izbrane izmed N, NR11, O in S); kjer je omenjeni heteroaril substituiran z 0-1 R12; kadar sta dve skupini R2 vezani na dva različna ogljikova atoma, se lahko združita, da tvorita 1- do 3-členski ogljikov atomski most nad obročem B; kadar sta dve skupini R2 vezani na isti ogljik, lahko skupaj z ogljikovim atomom, na katerega sta vezana, tvorita 3- do 6-členski ogljikov atom, ki vsebuje spiro obroč; R3 je neodvisno izbran izmed: C1-6 alkila substituiranega z R10, C2-6 alkenila substituiranega z R10, C2-6 alkinila substituiranega z R10 C1-4 haloalkila substituiranega z R10, -0(CH2)i-20(CH2)i-4R10, OR9, SR9, C(0)OR9, CO2R9, S(0)R9, SO2R9, in CONHR9; R4 in R4a sta neodvisno izbrana izmed: H, halogena, C1-6 alkila, C1-6 alkoksija, in -(CH2)m-C3-6 karbocikla; R5 je v vsakem primeru, neodvisno izbran izmed: halogena, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila, in C1-6 haloalkoksija; R6, je v vsakem primeru, neodvisno izbran izmed: halogena, OH, C1-4 alkiltia, CN, S02(Ci-2 alkila), N(Ci-4alkila)2, C1-4 haloalkila, C1-4 haloalkoksija, C1-8 alkila substituiranega z 0-1 R7, C1-6 alkoksija substituiranega z 0-1 R7, -(0)n-(CH2)m-(C3-io karbocikel, substituiran z 0- 2 R7), in -(CH2)m-(5- do 10-členski heteroaril ki vsebuje atome ogljika in 1- 4 heteroatome izbrane izmed N, NR11, O, in S); kjer je omenjeni heteroaril substituiran z 0-2 R7; R7, je v vsakem primeru neodvisno izbran izmed: halogena, OH, C1-4 alkila, C2-4 alkenila, C1-4 alkoksija, C-m alkiltia, C1-4 haloalkila, Cm haloalkoksija, SCF3, CN, NO2, NH2, NH(Cm alkila), N(Cm alkila)2, S02(Ci-2 alkila), in fenila; R8 je neodvisno izbran izmed: H in Cm alkila; R9, je v vsakem primeru neodvisno izbran izmed: C1-6 alkila substituiranega z R10, in Cm haloalkila substituiranega z R10; R10, je v vsakem primeru neodvisno izbran izmed: CN, Cm alkoksija, Cm haloalkoksija, C02(Cm alkila), S02(Cm alkila), in tetrazolila; R11, je v vsakem primeru neodvisno izbran izmed: H, Cm alkila in benzila R12, je v vsakem primeru neodvisno izbran izmed: OH, halogena, CN, Cm alkila, Cm alkoksija, Cm haloalkila, Cm haloalkoksija, C02(Cm alkila), in tetrazolila; m, je v vsakem primeru neodvisno 0, 1, ali 2; in n, je v vsakem primeru neodvisno 0 ali 1.
  2. 2. Spojina po zahtevku 1, kjer je R4 vodik in R8 je vodik, nadalje označena s formulo (II):
    ali njena stereoizomera, tavtomera, farmacevtsko sprejemljiva sol, polimorf ali solvat, kjer:: Xje neodvisno izbran izmed: O, N(CH3), CH2, CH2O in CH2CH2O; obroč A je neodvisno
    obroč B je neodvisno 4- do 7-členski nasičeni heterocikel, ki vsebuje atome ogljika in dušikov atom prikazan v obroču B; in obroč B je substituiran z 0-4 R2; R1 je neodvisno
    fenil, benzil, naftil ali 5- do 10-členski heteroaril, ki vsebuje atome ogljika in 1-4 heteroatome izbrane izmed N, NR11, O, in S; kjer so omenjeni fenil, benzil, naftil in heteroaril vsak substituiran z 0-3 R6; R2, je v vsakem primeru neodvisno izbran izmed: =0, OH, halogena, C-m alkila substituiranega z 0-1 R12, C1-4 alkoksija substituiranega z 0-1 R12, Cm haloalkila, Cm haloalkoksija, in benzila; kadar sta dve skupini R2 vezani na dva različna ogljikova atoma, se lahko združita, da tvorita 1- do 3-členski ogljikov atomski most nad obročem B; kadar sta dve skupini R2 pritrjeni na isti ogljik, lahko skupaj z ogljikovim atomom, na katerega sta vezana, tvorita 3- do 6-členski ogljikov atom, ki vsebuje spiro obroč; R3 je neodvisno izbran izmed: Cu alkila substituiranega z R10, C14 alkoksija substituiranega z R10, Cm haloalkila substituiranega z R10, Cm haloalkoksija substituiranega z R10, OR9, in -0(CH2)i-20(CH2)m R10; R4a je neodvisno izbran izmed: H, halogena, Cm alkila, Cm alkoksija, in -(CH2)m-C3-6 karbocikla; R5, je v vsakem primeru neodvisno izbran izmed: halogena, Cm alkila, Cm haloalkila, Cm alkoksija, in Cm haloalkoksija; R6, je v vsakem primeru neodvisno izbran izmed: halogena, OH, Cm alkiltia, CN, S02(Ci-2 alkila), N(Cm alkila)2, Cm haloalkila, Cm haloalkoksija, Cm alkila substituiranega z 0-1 R7, Cm alkoksija substituiranega z 0-1 R1, -(0)n-(CH2)m-(C3-6 karbocikel substituiran z 0-2 R7), -(CH2)m-(naftil substituiran z 0-2 R7), in -(CH2)m-(5- do 10-členskega heteroarila, ki vsebuje atome ogljika in 1-4 heteroatome izbrane izmed N, O, and S; kjer je omenjeni heteroaril substituiran z 0-2 R7); R7, je v vsakem primeru neodvisno izbran izmed: halogena, OH, Cm alkila, C2-4 alkenila, Cm alkoksija, Cm alkiltia, Cm haloalkila, Cm haloalkoksija, SCF3, CN, NO2, NH2, NH(Ci-4 alkila), N(Cm alkila)2, S02(Ci-2 alkila), in fenila; R9, je v vsakem primeru neodvisno izbran izmed: C1-6 alkila substituiranega z R10, in C1-4 haloalkila substituiranega z R10; R10, je v vsakem primeru neodvisno izbran izmed: CN, C1-4 alkoksija, C1-4 haloalkoksija, C02(Ci-4 alkila), S02(Ci-4 alkila), in tetrazolila; R11, je v vsakem primeru neodvisno izbran izmed: H, C1-4 alkila in benzila; R12, je v vsakem primeru neodvisno izbran izmed: halogena, CN, C1-4 alkila, C1-4 alkoksija, C1-4 haloalkila, C1-4 haloalkoksija, C02(Ci-4 alkila), in tetrazolila; m, je v vsakem primeru neodvisno 0,1, ali 2; in n, je v vsakem primeru neodvisno 0 ali 1.
  3. 3. Spojina po zahtevku 1 ali 2, kjer: obroč A je neodvisno
    obroč B je neodvisno izbran izmed:
    in
    R1 je neodvisno
    fenil substituiran z 0-3 R6 ali heteroaril substituiran z 0-2 R6; kjer je omenjeni heteroaril izbran izmed: furanila, oksazolila, tiazolila, pirazolila, oksadiazolila, piridinila, pirimidinila, pirazinila,
    R2, je v vsakem primeru neodvisno izbran izmed: OH, halogena, C1-4 alkila substituiranega z 0-1 R12, C-u alkoksija substituiranega z 0-1 R12, in benzila; R3 je neodvisno izbran izmed: C14 alkila substituiranega z 1 R10, Cm alkoksija substituiranega z 1 R10, C1-4 haloalkila substituiranega z 1 R10, OR9, in C1-4 haloalkoksija substituiranega z 1 R10; R4a je neodvisno izbran izmed: H, halogena Cm alkila, C1-4 alkoksija, in C3-6 cikloalkila; R6, je v vsakem primeru neodvisno izbran izmed: halogena, OH, C1-6 alkila substituiranega z 0-1 OH, C1-4 alkoksija, C1-4 alkiltia, C1-4 haloalkila, C1-4 haloalkoksija, CN, S02(Ci-2 alkila), N(Ci-4 alkila>2, C3-6 cikloalkila substituiranega z 0-2 C1-4 alkilom, C5-6 cikloalkenila substituiranega z 0-2 C1-4 alkilom, -O-C3-6 cikloalkilom, benzilom, in oksazolilom; R9, je v vsakem primeru neodvisno izbran izmed: C1-6 alkila substituiranega z R10, in C1-4 haloalkila substituiranega z R10 R10 je v vsakem primeru neodvisno izbran izmed: CN, C1-4 alkoksija, C1-4 haloalkoksija, C02(Ci-4 alkila), S02(Ci-4 alkila), in tetrazolila; in R12, je v vsakem primeru neodvisno izbran izmed: halogena, CN, C1-4 alkila, C1-4 alkoksija, C1-4 haloalkila, C1-4 haloalkoksija, C02(Ci-2 alkila), in tetrazolila.
  4. 4. Spojina po katerem koli od zahtevkov 1-3, kjer: R1 je neodvisno
    fenil substituiran z 0-3 R6, ali heteroaril substituiran z 0-2 R6; kjer je omenjeni heteroaril izbran izmed: tiazolila, piridinila, pirimidinila, pirazinila,
  5. 5. Spojina po katerem koli od zahtevkov 1-4, kjer: Obroč B neodvisno izbran izmed:
    R1 je neodvisno fenil substituiran z 0-3 R6, piridinil substituiran z 0-2 R6, pirazinil substituiran z 0-2 R6, pirimidinil substituiran z 0-2 R6, tiazolil substituiran z 0-2 R6, in
    R2, je v vsakem primeru, neodvisno izbran izmed: OH, halogena, Cm alkila substituiranega z 0-1 CN, C1-4 alkoksija, benzila, in tetrazolilmetila.
  6. 6. Spojina po katerem koli od zahtevkov 1-5, kjer: obroč B je neodvisno izbran izmed:
    R1, je v vsakem primeru, neodvisno fenil substituiran z 0-3 R6 ali piridinil substituiran z 0-2 R6; R2, je v vsakem primeru, neodvisno izbran izmed: halogena, Cm alkila, Cm alkoksija in tetrazolilmetila; R3, je v vsakem primeru, neodvisno izbran izmed: Cm alkila substituiranega z R10, Cm alkoksija substituiranega z R10, OR9, in -0(CH2)i-20(CH2)mR1°; R6, je v vsakem primeru, neodvisno izbran izmed: halogena, Ci-β alkila, Ci-4 alkoksija, Cm haloalkila, Cm haloalkoksija, C3-6 cikloalkila substituiranega z 0-2 Cm alkila, C5-6 cikloalkenila substituiranega z 0-2 C1-4 alkila, in benzila; R9, je v vsakem primeru, neodvisno izbran izmed: C1.6 alkila substituiranega R10, in Cm haloalkila substitiranega z R10; in R10, je v vsakem primeru, neodvisno izbran izmed: CN, Cm alkoksija, Cm haloalkoksija, C02(Cm alkila), S02(Cm alkila), in tetrazolila.
  7. 7. Spojina po zahtevku 1, ki ima formulo (lil), (lila), (lllb) ali (lile):
    ali njena stereoizomera, tavtomera, farmacevtsko sprejemljiva sol, polimorf ali solvat, kjer: R1, je v vsakem primeru, neodvisno fenil substituiran z 0-3 R6 ali piridinil substituiran z 0-2 R6; R2, je v vsakem primeru, neodvisno izbran izmed: halogena, Cm alkila, in Ci-4 alkoksija; R3, je v vsakem primeru, neodvisno izbran izmed: Cm alkila substituiranega z C1-4 alkoksijem, in C1-4 alkoksija substituiranega z C1-4 alkoksijem; R4a, je v vsakem primeru, neodvisno izbran izmed: H, halogena, Cm alkila, C1-4 alkoksija, in ciklopropila; R5 je v vsakem primeru, neodvisno izbran izmed: halogena, Cm haloalkila, in C1-6 alkoksija; in R6, je v vsakem primeru, neodvisno izbran izmed: halogena, C1-6 alkila, C1-4 alkoksija, C3-6 cikloalkila substituiranega z 0-2 Cm alkila, in C5-6 cikloalkenila substituiranega z 0-2 Cm alkila.
  8. 8. Spojina po zahtevku 7, kjer: R\ je v vsakem primeru, neodvisno fenil substituiran z 0-3 R6 ali piridinil substituiran z 0-2 R6; R2 je v vsakem primeru, neodvisno izbran izmed: halogena in C1-2 alkila; R3, je v vsakem primeru, neodvisno izbran izmed: C1-4 alkila substituiranega z C1-4 alkoksijem, in C1-4 alkoksi substituiran z C1-4 alkoksijem; R4a, je v vsakem primeru, neodvisno izbran izmed: H in metila; R5, je v vsakem primeru, neodvisno izbran izmed: halogena, C1-4 haloalkila, in C1-6 alkoksija; in R6, je v vsakem primeru, neodvisno izbran izmed: halogena, C1-6 alkila, in C1-4 alkoksija.
  9. 9. Spojina po zahtevku 1, ki je izbrana izmed
    ali njena stereoizomera, tavtomera, farmacevtsko sprejemljiva sol, polimorf ali solvat.
  10. 10. Spojina po zahtevku 1, ki je izbrana izmed
    ali njena stereoizomera, tavtomera, farmacevtsko sprejemljiva sol, polimorf ali solvat.
  11. 11. Farmacevtski sestavek, ki obsega farmacevtsko sprejemljiv nosilec in spojino po katerem koli od zahtevkov 1-10 in po izbiri nadalje vsebuje eno ali več drugih primernih terapevtskih sredstev, izbranih izmed: anti-diabetičnih sredstev, anti-hiperglikemičnih sredstev, anti-hiperinsulinemičnih sredstev, anti-retinopatskih sredstev, anti-neuropatskih sredstev, anti-nefropatskih sredstev, antiatherosklerotičnih sredstev, anti-ishemičnih sredstev, anti-hipertenzivnih sredstev, sredstev proti debelosti, anti-disilipidemskih sredstev, anti-hiperlipidemičnih sredstev, anti-hipertrigliceridemskih sredstev, anti-hiperholesterolemičnih sredstev, anti-restenotičnih sredstev, sredstev proti pankreasu, sredstev za zniževanje lipidov, anorektičnih sredstev in sredstev za zatiranje apetita.
  12. 12. Farmacevtski sestavek po zahtevku 11, ki nadalje obsega inhibitor dipeptidil peptidaze-IV in/ali inhibitor natrijevega glukoznega transporterja-2.
  13. 13. Spojina po katerem koli od zahtevkov 1-10, za uporabo pri terapiji.
  14. 14. Spojina po katerem koli od zahtevkov 1 do 10 za uporabo pri zdravljenju sladkorne bolezni, hiperglikemije, okvare na toleranco glukoze, gestacijskega diabetesa, insulinske rezistence, hiperinsulinemije, retinopatije, nevropatije, nefropatije, diabetične bolezni ledvic, akutne poškodbe ledvic, kardiorenalnega sindroma, akutnega koronarnega sindroma, zakasnjenega celjenja ran, ateroskleroze in njenih posledic, nenormalnega delovanja srca, kongestivnega srčnega popuščanja, ishemičnega miokarda, možganske kapi, metaboličnega sindroma, hipertenzije, debelosti, bolezni zamaščenih jeter, dislipidemije, dislipidemije, hiperlipidemija, hipertrigliceridemije, hiperholesterolemije, (LDL), ne-srčne ishemije, pankreatitisa, lipidnih motenj in bolezni jeter, kot so NASH (nealkoholni steathepatitis), NAFLD (bolezen brezalkoholnih zamaščenih jeter), jetrne ciroze , vnetnih črevesnih bolezni, ki vključujejo ulcerozni kolitis in Crohnovo bolezen, celiakije, osteoartritisa, nefritisa, psoriaze, atopijskega dermatitisa in vnetja kože.
  15. 15. Spojina za uporabo po zahtevku 13 ali zahtevku 14, kjer se spojina po katerem koli od zahtevkov 1-10 uporablja istočasno, ločeno ali zaporedno z enim ali večimi dodatnimi terapevtskimi sredstvi.
SI201530232T 2014-05-07 2015-05-06 Pirolidin gpr40 modulatorji za zdravljenje bolezni kot je sladkorna bolezen SI3140296T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989651P 2014-05-07 2014-05-07
PCT/US2015/029409 WO2015171722A1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EP15723095.4A EP3140296B1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Publications (1)

Publication Number Publication Date
SI3140296T1 true SI3140296T1 (sl) 2018-06-29

Family

ID=53181359

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530232T SI3140296T1 (sl) 2014-05-07 2015-05-06 Pirolidin gpr40 modulatorji za zdravljenje bolezni kot je sladkorna bolezen

Country Status (32)

Country Link
US (4) US9873679B2 (sl)
EP (1) EP3140296B1 (sl)
JP (1) JP6483156B2 (sl)
KR (1) KR102336370B1 (sl)
CN (1) CN106458976B (sl)
AR (1) AR100328A1 (sl)
AU (1) AU2015256120B2 (sl)
BR (1) BR112016024936A2 (sl)
CA (1) CA2948161C (sl)
CL (1) CL2016002809A1 (sl)
CY (1) CY1120340T1 (sl)
DK (1) DK3140296T3 (sl)
EA (1) EA033250B1 (sl)
ES (1) ES2674531T3 (sl)
HR (1) HRP20180641T1 (sl)
HU (1) HUE039288T2 (sl)
IL (1) IL248668B (sl)
MA (1) MA39427B1 (sl)
MX (1) MX2016013801A (sl)
MY (1) MY181959A (sl)
NZ (1) NZ727146A (sl)
PE (1) PE20161363A1 (sl)
PH (1) PH12016502034B1 (sl)
PL (1) PL3140296T3 (sl)
PT (1) PT3140296T (sl)
RS (1) RS57170B1 (sl)
SG (1) SG11201609170UA (sl)
SI (1) SI3140296T1 (sl)
TN (1) TN2016000444A1 (sl)
TR (1) TR201809633T4 (sl)
TW (1) TWI659951B (sl)
WO (1) WO2015171722A1 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016025188A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de pirrolidina gpr40 para o tratamento de doenças tal como diabetes
EA033250B1 (ru) * 2014-05-07 2019-09-30 Бристол-Майерс Сквибб Компани Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
EP3509588B1 (en) 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
EP3509587B1 (en) 2016-09-12 2023-12-06 Valo Health, Inc. Monocyclic compounds useful as gpr120 modulators
CA3058578A1 (en) * 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Aromatic compound
CN110947003B (zh) * 2017-08-21 2021-04-02 武汉大学 Gpr31抑制剂在制备治疗肾脏缺血再灌注损伤及相关疾病药物中的应用
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112023023420A2 (pt) 2021-06-16 2024-01-30 Celgene Corp Compostos de azetidinila compreendendo um grupo ácido carboxílico para o tratamento de doenças neurodegenerativas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP2486005B1 (en) * 2009-10-06 2014-06-18 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
US7939569B1 (en) * 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
US9120798B2 (en) 2012-08-01 2015-09-01 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor
DK2920165T3 (en) 2012-11-16 2017-01-16 Bristol Myers Squibb Co Dihydropyrazol-GPR40-MODULATORS
SG11201503562PA (en) 2012-11-16 2015-06-29 Bristol Myers Squibb Co Dihydropyrazole gpr40 modulators
CN105121426B (zh) * 2012-11-16 2017-03-29 百时美施贵宝公司 吡咯烷gpr40调节剂
CN104918935B (zh) 2012-11-16 2017-07-28 百时美施贵宝公司 二氢吡唑gpr40调节剂
DK3139903T3 (da) 2014-05-07 2019-09-09 Croma Pharma Ges M B H Vandig oftalmisk opløsning og fremgangsmåde til behandling af tørre øjne-syndrom
US10301260B2 (en) 2014-05-07 2019-05-28 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
EA033250B1 (ru) * 2014-05-07 2019-09-30 Бристол-Майерс Сквибб Компани Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет

Also Published As

Publication number Publication date
EA201692037A1 (ru) 2017-06-30
US20200299267A1 (en) 2020-09-24
HRP20180641T1 (hr) 2018-06-01
RS57170B1 (sr) 2018-07-31
BR112016024936A2 (pt) 2017-08-15
PH12016502034A1 (en) 2017-01-09
HUE039288T2 (hu) 2018-12-28
EP3140296B1 (en) 2018-04-11
MY181959A (en) 2021-01-15
CA2948161A1 (en) 2015-11-12
US9873679B2 (en) 2018-01-23
JP6483156B2 (ja) 2019-03-13
TR201809633T4 (tr) 2018-07-23
TWI659951B (zh) 2019-05-21
DK3140296T3 (en) 2018-07-23
EA033250B1 (ru) 2019-09-30
MA39427A1 (fr) 2017-11-30
PL3140296T3 (pl) 2018-08-31
CL2016002809A1 (es) 2017-03-24
WO2015171722A1 (en) 2015-11-12
TW201625585A (zh) 2016-07-16
CN106458976B (zh) 2020-05-22
KR102336370B1 (ko) 2021-12-06
IL248668B (en) 2019-09-26
CY1120340T1 (el) 2019-07-10
AU2015256120A1 (en) 2016-12-22
ES2674531T3 (es) 2018-07-02
US20150322044A1 (en) 2015-11-12
SG11201609170UA (en) 2016-12-29
MX2016013801A (es) 2017-03-09
EP3140296A1 (en) 2017-03-15
AR100328A1 (es) 2016-09-28
CA2948161C (en) 2020-10-27
PT3140296T (pt) 2018-06-27
TN2016000444A1 (en) 2018-04-04
US10717725B2 (en) 2020-07-21
US20190112293A1 (en) 2019-04-18
IL248668A0 (en) 2017-01-31
JP2017514856A (ja) 2017-06-08
AU2015256120B2 (en) 2019-03-28
PH12016502034B1 (en) 2017-01-09
KR20160147049A (ko) 2016-12-21
NZ727146A (en) 2020-01-31
PE20161363A1 (es) 2016-12-17
MA39427B1 (fr) 2018-09-28
CN106458976A (zh) 2017-02-22
US20180099949A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
SI3140296T1 (sl) Pirolidin gpr40 modulatorji za zdravljenje bolezni kot je sladkorna bolezen
HRP20161011T1 (hr) Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2
HRP20190668T1 (hr) Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori
SI3099687T1 (sl) Makrocikli z heterocikličnimi p2' skupinami kot faktor xia inhibitorjev
RU2015100901A (ru) Производные эфира гетероарилкарбоновой кислоты
KR102610573B1 (ko) 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법
HRP20240861T1 (hr) Derivati 6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dihlorofenil)-2-metilpirimidin-4(3h)-ona i srodni spojevi kao inhibitori ptpn11 (shp2) za liječenje raka
JP2016520128A5 (sl)
HRP20161631T1 (hr) Dihidropirazolni gpr40 modulatori
JP2016506962A5 (sl)
JP2012507566A5 (sl)
JP2017508794A5 (sl)
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
JP2017508795A5 (sl)
JP2016506959A5 (sl)
RU2012151012A (ru) Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием
JP2009514887A5 (sl)
CA2443950A1 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
HRP20130213T1 (hr) Spojevi morfinana
JP2017528467A5 (sl)
CA2601508A1 (en) Cyclopropanecarboxamide derivatives
JP2016506960A5 (sl)
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
RU2008142360A (ru) Производные амидов и их применение для лечения нарушений, связанных с белком g
JP2007532651A5 (sl)